Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith C Bible

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Nature Reviews. Clinical Oncology|March 2, 2016
Evolving molecularly targeted therapies for advanced-stage thyroid cancersKeith C Bible, Mabel Ryder
Expert Opinion on Investigational Drugs|September 14, 2011
Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approachesPamela Jo Harris, Keith C Bible
Endocrine-Related Cancer|May 18, 2016
New drugs for medullary thyroid cancer: new promises?Christine Spitzweg, John C Morris, Keith C Bible
Antioxidants & Redox Signaling|February 23, 2010
Annatto constituent cis-bixin has selective antimyeloma effects mediated by oxidative stress and associated with inhibition of thioredoxin and thioredoxin reductaseJennifer D Tibodeau, Crescent R Isham, Keith C Bible
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|January 24, 2014
Systemic therapeutic approaches to advanced thyroid cancersMichael E Menefee, Robert C Smallridge, Keith C Bible
Journal of Bone Oncology|March 11, 2020
Bone metastases in thyroid cancerNicole M Iñiguez-Ariza, Keith C Bible, Bart L Clarke
The Lancet. Diabetes & Endocrinology|June 6, 2014
Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targetsChristine Spitzweg, Keith C Bible, Lorenz C Hofbauer, et al.
Molecular Cancer Therapeutics|January 25, 2006
Flavopiridol disrupts STAT3/DNA interactions, attenuates STAT3-directed transcription, and combines with the Jak kinase inhibitor AG490 to achieve cytotoxic synergyYean Kit Lee, Crescent R Isham, Scott H Kaufman, et al.
Endocrinology and Metabolism Clinics of North America|February 6, 2019
Diagnosis and Management of Anaplastic Thyroid CancerAshish V Chintakuntlawar, Robert L Foote, Jan L Kasperbauer, et al.
Thyroid : Official Journal of the American Thyroid Association|May 5, 2017
Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid CancerNicole M Iñiguez-Ariza, Mabel M Ryder, Crystal R Hilger, et al.
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Nature Reviews. Clinical Oncology|March 2, 2016
Evolving molecularly targeted therapies for advanced-stage thyroid cancersKeith C Bible, Mabel Ryder
Expert Opinion on Investigational Drugs|September 14, 2011
Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approachesPamela Jo Harris, Keith C Bible
Endocrine-Related Cancer|May 18, 2016
New drugs for medullary thyroid cancer: new promises?Christine Spitzweg, John C Morris, Keith C Bible
Antioxidants & Redox Signaling|February 23, 2010
Annatto constituent cis-bixin has selective antimyeloma effects mediated by oxidative stress and associated with inhibition of thioredoxin and thioredoxin reductaseJennifer D Tibodeau, Crescent R Isham, Keith C Bible
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|January 24, 2014
Systemic therapeutic approaches to advanced thyroid cancersMichael E Menefee, Robert C Smallridge, Keith C Bible
Journal of Bone Oncology|March 11, 2020
Bone metastases in thyroid cancerNicole M Iñiguez-Ariza, Keith C Bible, Bart L Clarke
The Lancet. Diabetes & Endocrinology|June 6, 2014
Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targetsChristine Spitzweg, Keith C Bible, Lorenz C Hofbauer, et al.
Molecular Cancer Therapeutics|January 25, 2006
Flavopiridol disrupts STAT3/DNA interactions, attenuates STAT3-directed transcription, and combines with the Jak kinase inhibitor AG490 to achieve cytotoxic synergyYean Kit Lee, Crescent R Isham, Scott H Kaufman, et al.
Endocrinology and Metabolism Clinics of North America|February 6, 2019
Diagnosis and Management of Anaplastic Thyroid CancerAshish V Chintakuntlawar, Robert L Foote, Jan L Kasperbauer, et al.
Thyroid : Official Journal of the American Thyroid Association|May 5, 2017
Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid CancerNicole M Iñiguez-Ariza, Mabel M Ryder, Crystal R Hilger, et al.
Pageof 6